Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por ...

Fabhalta, a therapy for a rare blood disease, earned the green light in 2023, while Vanrafia, a medicine for a kidney disease, did so just this month. Novartis' deep pipeline will lead to more ...

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

5 Safe Dividend Stocks Yielding 5% or More to Buy Right Now for Durable Passive Income The stock market has slumped sharply this year due to concerns that tariffs could cause a recession. One ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Manufacturing problems wreaked havoc with Mallinckrodt's first attempt to secure FDA approval of its treatment candidate terlipressin for hepatorenal syndrome (HRS), but the drugmaker is having ...

Swiss pharma major Novartis (NOVN: VX) has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending hopes for a new therapy in the anti-ADAMTS-5 class. The company ...

Previously, the treatment had only been supplied in a single-dose vial that required administration by a health care professional using a winged infusion set. The Food and Drug Administration (FDA) ...